Skip to main content
SRPT
NASDAQ Life Sciences

Sarepta Q3 Revenue Slips 5% as ELEVIDYS Declines, but Guidance Low End Raised $50M

Tom Rudovsky · Reported by BusinessWire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$16.65
Mkt Cap
$1.856B
52W Low
$14.68
52W High
$24.68
52W Position info
13% above low
Off High info
33% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

SRPT is trading near its 52-week low of $14.68 (13% above the low).

Summary

Sarepta reported Q3 2026 total revenues of $381.4 million, down 5% from $399.4 million a year earlier, as ELEVIDYS sales fell on the narrower ambulatory-only label. The quarter produced a GAAP net loss of $28.5 million, or $0.27 per share, versus a $50.6 million loss a year ago, while non-GAAP net income came in at $15.6 million, or $0.13 per share. Cost of sales included a $62.0 million take-or-pay charge tied to Catalent manufacturing obligations the company elected not to fulfill. Management raised the low end of full-year total net product revenue guidance by $50.0 million to $1.25-$1.3 billion and trimmed the high end of combined non-GAAP R&D and SG&A expense guidance by $25.0 million to $800-$825 million. The balance sheet holds $998.7 million in cash, cash equivalents, restricted cash and investments, which the company says funds the DM1 and FSHD programs through late-stage development. Multiple ascending dose data for SRP-1003 in DM1 and SRP-1001 in FSHD are expected in Q4 2026, with Phase 3 preparations already underway.

At the time of this announcement, SRPT was trading at $16.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $14.68 to $24.68. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: BusinessWire.


Price Chart

Share this article

Copied!

SRPT - Latest Insights

SRPT
Nov 05, 2026, 4:10 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $17.93
Real-time Price: $13.60 info
Change: -$4.33 (-24%) info
Market Cap: $1.429B info
SRPT
Nov 05, 2026, 4:01 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $17.57
Real-time Price: $13.60 info
Change: -$3.97 (-23%) info
Market Cap: $1.429B info
SRPT
Sep 30, 2026, 8:30 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $18.64
Real-time Price: $13.60 info
Change: -$5.04 (-27%) info
Market Cap: $1.429B info
SRPT
Sep 23, 2026, 4:18 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $19.03
Real-time Price: $13.60 info
Change: -$5.43 (-29%) info
Market Cap: $1.429B info
SRPT
Jul 27, 2026, 9:08 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $16.35
Real-time Price: $13.60 info
Change: -$2.75 (-17%) info
Market Cap: $1.429B info